Pfizer Antes Up $110 Million To Buy In To Cancer Cell Therapy Race - Presented by: The Aol. On Network

Fresh from its failed (or at least paused) attempt to acquire rival AstraZeneca, Pfizer has made a big bet on one of the hottest new technologies in cancer: genetically engineered white blood cells that hunt down tumors and destroy them. Pfizer announced this morning that it will pay Cellectis, a French biotechnology company, an $80 million upfront payment for the company’s T-cell technology, in addition to purchasing about $30 million in stock.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
BAC $ 16.01 0.20 ▲ 1.27%
AAPL $ 129.09 0.63 ▲ 0.49%
CSCO $ 30.19 0.68 ▲ 2.30%
PBR $ 6.37 0.26 ▼ 3.92%
JCP $ 7.85 0.65 ▼ 7.65%
GE $ 26.11 0.12 ▲ 0.46%
ARUN $ 24.65 0.16 ▼ 0.64%
MSFT $ 43.88 0.03 ▲ 0.07%

As of 3/2/2015, 04:15 PM
More Most Active